Janux Therapeutics Inc [NASDAQ: JANX] loss -9.40% or -3.09 points to close at $29.79 with a heavy trading volume of 1771446 shares.
The daily chart for JANX points out that the company has recorded -46.76% loss over the past six months.
If we look at the average trading volume of 907.22K shares, JANX reached to a volume of 1771446 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Janux Therapeutics Inc [JANX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JANX shares is $89.27 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JANX stock is a recommendation set at 1.15. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Janux Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 03, 2024. While these analysts kept the previous recommendation, BTIG Research dropped their target price from $82 to $100. The new note on the price target was released on December 03, 2024, representing the official price target for Janux Therapeutics Inc stock. Previously, the target price had yet another raise to $79, while Leerink Partners analysts kept a Outperform rating on JANX stock.
The Average True Range (ATR) for Janux Therapeutics Inc is set at 1.99, with the Price to Sales ratio for JANX stock in the period of the last 12 months amounting to 166.44. The Price to Book ratio for the last quarter was 1.72, with the Price to Cash per share for the same quarter was set at 17.33.
Trading performance analysis for JANX stock
Janux Therapeutics Inc [JANX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.57. With this latest performance, JANX shares gained by 10.37% in over the last four-week period, additionally sinking by -46.76% over the last 6 months – not to mention a drop of -48.81% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JANX stock in for the last two-week period is set at 47.07, with the RSI for the last a single of trading hit 44.47, and the three-weeks RSI is set at 46.60 for Janux Therapeutics Inc [JANX]. The present Moving Average for the last 50 days of trading for this stock 30.11, while it was recorded at 32.09 for the last single week of trading, and 43.15 for the last 200 days.
Janux Therapeutics Inc [JANX]: A deeper dive into fundamental analysis
Janux Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 59.21 and a Current Ratio set at 59.21.
An analysis of Institutional ownership at Janux Therapeutics Inc [JANX]
The top three institutional holders of JANX stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 9.17 million shares, which is approximately 16.8326%. FMR LLC, holding 7.78 million shares of the stock with an approximate value of $$325.8 million in JANX stocks shares; and FMR LLC, currently with $$124.82 million in JANX stock with ownership which is approximately 5.4724%.
